ClinicalTrials.Veeva

Menu

Young Adults' Reactions to Low Nicotine Cigarette Advertising (YLA)

Abramson Cancer Center at Penn Medicine logo

Abramson Cancer Center at Penn Medicine

Status

Completed

Conditions

Smoking

Treatments

Other: Advertisement content (true vs. misleading)
Other: Advertisement content (explicit vs. implicit)

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT04906148
K07CA218366 (U.S. NIH Grant/Contract)
844887
UPCC 03021

Details and patient eligibility

About

Reducing the nicotine content in combustible cigarettes to non-addictive levels has demonstrated promise as a safe and effective public health strategy for decreasing tobacco-caused morbidity and mortality. Little data are available, however, assessing how the marketing of low nicotine content (LNC) cigarettes could dampen their potential population health benefit. This study will examine LNC cigarette advertising content effects on message recall, viewing patterns, product perceptions, and use behaviors. Young adults (N = 340; 170 smokers, 170 non-smokers) will complete a single-session laboratory study using a 2 x 2 between-subject design to manipulate advertisement messaging accuracy (true vs. false/misleading) and content (implicit vs. explicit). Findings may be used to guide public health policy decisions related to regulating cigarette nicotine content and marketing.

Enrollment

56 patients

Sex

All

Ages

21 to 29 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Aged 21-29
  • Able to use a computer or related technology (such as a smartphone or tablet) with reliable internet access and willing to use the device to participate in the research study.
  • Have a valid email address and willing to use email to participate in the research study. Participants without an existing email account who are willing to create one for study purposes are eligible to participate.

Additional inclusion criteria vary by smoking status.

Exclusion criteria

  • Currently enrolled in a cessation program
  • Report consuming ≥ 25 alcohol-containing drinks per week
  • Report a history or current psychiatric diagnosis or severe medical condition
  • Are color-blind or have another visual impairment (e.g., partial blindness, uncorrected cataract)
  • Self-report being pregnant and/or lactating
  • Are diagnosed with or test positive for COVID-19. Participants who report having traveled to a high-risk area in the past 2 weeks or who have been in close contact with someone confirmed or being evaluated for COVID-19 will be placed on a waitlist. Waitlisted participants will be asked to self-isolate for 14 days after exposure (even without symptoms) and will be re-screened for eligibility post self-isolation.

Additional, general reasons for exclusion include:

  • Significant non-compliance with protocol and/or study design as determined by the Principal Investigator (PI) at any point throughout the study.
  • Past, current, anticipated, or pending enrollment in another research program over the study period that could potentially impact study data as determined by the PI.
  • Any medical condition, illness, disorder, adverse event (AE), or concomitant medication that could compromise participant safety or significantly impact study performance as determined by the PI. Subjects may be deemed ineligible for any of the aforementioned reasons at any point throughout the study, as well as during the initial telephone screen.

Trial design

Primary purpose

Other

Allocation

Randomized

Interventional model

Factorial Assignment

Masking

Single Blind

56 participants in 2 patient groups

Smokers
Experimental group
Description:
Smokers will be randomized to view an advertisement with either true or misleading and implicit or explicit harm messaging content.
Treatment:
Other: Advertisement content (explicit vs. implicit)
Other: Advertisement content (true vs. misleading)
Non-smokers
Experimental group
Description:
Non-smokers will be randomized to view an advertisement with either true or misleading and implicit or explicit harm messaging content.
Treatment:
Other: Advertisement content (explicit vs. implicit)
Other: Advertisement content (true vs. misleading)

Trial contacts and locations

1

Loading...

Central trial contact

Melissa Mercincavage, PhD; Valentina Souprountchouk, BA

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems